ArticleFrontiers in immunology2026
The capability of deep-radiomics to predict pathological response to neoadjuvant immunochemotherapy in non-small cell lung cancer: a retrospective multicenter study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To establish a predictive model that combines radiomics, deep learning and clinical features for predicting the pathological complete response (pCR) of non-small cell lung cancer (NSCLC) patients after neoadjuvant immunochemotherapy (NIT). Methods: We retrospectively collected patients from three centers (split into training, internal testing and external testing cohorts). In this study, tumor segmentation was performed on chest CT images before (pre-NIT) and after (post-NIT) neoadjuvant therapy. The radiomics features were extracted from pre-NIT and post-NIT images. Deep learning (DL) features were extracted from the post-NIT images. The most meaningful features were selected using the mRMR and LASSO. A logistic regression classifier was then applied to create a classification model to predict pCR or non-pCR. The predicted probabilities were referred to as the Rad-scores and Deep-scores. Finally, Rad-scores, Deep-scores, and meaningful clinical features were fused to build a combined model. Results: A total of 178 patients were enrolled in the current study. In conventional radiomics, the efficacy of post-NIT model was better than the pre-NIT. In delta radiomics model, delta1 had the best efficacy. Subsequently, the post-NIT and delta1 features were further constructed as the combined model 1 with AUCs of 0.939 and 0.849, respectively. iRECIST was combined with the radiomics and the DL features to establish the combined model 2, which achieved the best performance among all the models, with AUCs of 0.955(training), 0.882(In-testing), and 0.839(Ex-testing). Conclusions: Our results demonstrated that combination of three dimensional features can provide complementary information to predict pCR more accurately.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.